Evidence map›Paper›PMID 42416072›Full record

ArticleFrontiers in immunology2026

Protective outcomes of high-affinity monoclonal antibodies against drug-resistant plague strains.

Wenxuan Peng, Hailian Wu, Li Zhang, Binyang Zheng, Qi Zhang, Wenyuan Xin, Xiaoyan Yang, Kaiye Ying, Ru Ma, Hongxing Pan and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Wenxuan PengQinghai Institute for Endemic Diseases Prevention and Control, Key Laboratory for Plague Prevention and Control of Qinghai Province, Xining, Qinghai, China.
Hailian WuQinghai Institute for Endemic Diseases Prevention and Control, Key Laboratory for Plague Prevention and Control of Qinghai Province, Xining, Qinghai, China.
Li ZhangJiangsu Provincial Center for Disease Prevention and Control, Department of Vaccine Clinical Evaluation, Nanjing, Jiangsu, China.
Binyang ZhengJiangsu Provincial Center for Disease Prevention and Control, Department of Vaccine Clinical Evaluation, Nanjing, Jiangsu, China.
Qi ZhangNHC Key Laboratory of Plague Prevention and Control, Qinghai Institute for Endemic Disease Prevention and Control, Xining, Qinghai, China.
Wenyuan XinQinghai Institute for Endemic Diseases Prevention and Control, Key Laboratory for Plague Prevention and Control of Qinghai Province, Xining, Qinghai, China.
Xiaoyan YangQinghai Institute for Endemic Diseases Prevention and Control, Key Laboratory for Plague Prevention and Control of Qinghai Province, Xining, Qinghai, China.
Kaiye YingQinghai Institute for Endemic Diseases Prevention and Control, Key Laboratory for Plague Prevention and Control of Qinghai Province, Xining, Qinghai, China.
Ru MaQinghai Institute for Endemic Diseases Prevention and Control, Key Laboratory for Plague Prevention and Control of Qinghai Province, Xining, Qinghai, China.
Hongxing PanJiangsu Provincial Center for Disease Prevention and Control, Department of Vaccine Clinical Evaluation, Nanjing, Jiangsu, China.
Qingwen ZhangQinghai Institute for Endemic Diseases Prevention and Control, Key Laboratory for Plague Prevention and Control of Qinghai Province, Xining, Qinghai, China.
Haisheng WuQinghai Institute for Endemic Diseases Prevention and Control, Key Laboratory for Plague Prevention and Control of Qinghai Province, Xining, Qinghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Methods: Here, we constructed an antibody library from Results: For the Conclusion: These findings indicated that mAbs Fm3 and Fm25 confer protection against virulent and drug-resistant strains of

Indexed as

Antibodies, BacterialAntibodies, MonoclonalDrug Resistance, BacterialPlagueYersinia pestisAnimalsAntibody AffinityAntigens, BacterialBacterial ProteinsDisease Models, AnimalFemaleMiceMice, Inbred BALB CPlague VaccineAntibodies, BacterialAntibodies, MonoclonalAntigens, BacterialBacterial ProteinsPlague Vaccinedrug-resistant infectionefficacy assessment in animal modelsnovel anti-plague monoclonal antibodiesnovel treatment modalities for plagueYersinia pestis

Identifiers

PMID42416072
PMCPMC13337711

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.